Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) EPS (Weighted Average and Diluted) (2023 - 2025)

Goldenwell Biotech (GWLL) has disclosed EPS (Weighted Average and Diluted) for 3 consecutive years, with -$0.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 68.27% year-over-year to -$0.0, compared with a TTM value of -$0.0 through Sep 2025, up 68.27%, and an annual FY2024 reading of -$0.0, down 12.05% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.0 for Q3 2025 at Goldenwell Biotech, down from -$0.0 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.0 in Q4 2024 and bottomed at -$0.0 in Q2 2024.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$0.0, with a median of -$0.0 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) soared 436.87% in 2024, then decreased 10.69% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.0 in 2023, then surged by 436.87% to $0.0 in 2024, then plummeted by 111.7% to -$0.0 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for GWLL at -$0.0 in Q3 2025, -$0.0 in Q2 2025, and -$0.0 in Q1 2025.